References
- Herbst R, Khuri F. Mode of action of docetaxel—a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29:407–415
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
- Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology. 2002;109:1188–1191
- Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98:504–507
- Esmaeli B, Burnstine M, Ahmadi A, et al. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Oph Plast Reconst Surg. 2003;19:4305–4308
- Skolnick CA, Doughman DJ. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens. 2003;29:134–135
- Schmid K, Kornek G, Scheithauer W, et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51:19–40
- Valero V, Holmes F, Walters R, et al. Phase II study of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic cancer. J Clin Oncol. 1995;13:2886–2894